New hope for nerve disorder patients through special access program
NCT ID NCT04777734
Summary
This program provides early access to an investigational treatment called efgartigimod PH20 SC for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder. It's designed for patients who can't join regular clinical trials and haven't found relief from currently available treatments. The program allows eligible patients to receive this treatment before it's widely approved, continuing until they stop treatment or insurance coverage becomes available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIDP are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.